Toll Free: 1-888-928-9744

Argos Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Aug, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Argos Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Argos Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Argos Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Argos Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Argos Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Argos Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Argos Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Argos Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Argos Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Argos Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Argos Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Argos Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Argos Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Argos Therapeutics, Inc. Snapshot 5
Argos Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Argos Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Argos Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Argos Therapeutics, Inc. - Pipeline Products Glance 10
Argos Therapeutics, Inc. - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Argos Therapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Argos Therapeutics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Argos Therapeutics, Inc. - Drug Profiles 14
AGS-003 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AGS-004 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AGS-009 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AGS-010 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Argos Therapeutics, Inc. - Pipeline Analysis 22
Argos Therapeutics, Inc. - Pipeline Products by Target 22
Argos Therapeutics, Inc. - Pipeline Products by Route of Administration 23
Argos Therapeutics, Inc. - Pipeline Products by Molecule Type 24
Argos Therapeutics, Inc. - Pipeline Products by Mechanism of Action 25
Argos Therapeutics, Inc. - Recent Pipeline Updates 26
Argos Therapeutics, Inc. - Dormant Projects 32
Argos Therapeutics, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
AGS-003 33
AGS-004 33
MB-002 33
Argos Therapeutics, Inc. - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36
List of Tables
Argos Therapeutics, Inc., Key Information 5
Argos Therapeutics, Inc., Key Facts 5
Argos Therapeutics, Inc. - Pipeline by Indication, 2014 7
Argos Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8
Argos Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9
Argos Therapeutics, Inc. - Phase III, 2014 10
Argos Therapeutics, Inc. - Phase II, 2014 11
Argos Therapeutics, Inc. - Phase I, 2014 12
Argos Therapeutics, Inc. - Preclinical, 2014 13
Argos Therapeutics, Inc. - Pipeline by Target, 2014 22
Argos Therapeutics, Inc. - Pipeline by Route of Administration, 2014 23
Argos Therapeutics, Inc. - Pipeline by Molecule Type, 2014 24
Argos Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 25
Argos Therapeutics, Inc. - Recent Pipeline Updates, 2014 26
Argos Therapeutics, Inc. - Dormant Developmental Projects,2014 32
Argos Therapeutics, Inc. - Discontinued Pipeline Products, 2014 33 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify